<DOC>
	<DOCNO>NCT00854113</DOCNO>
	<brief_summary>This study evaluate safety , tolerability pharmacokinetics single multiple dos EGT0001474 .</brief_summary>
	<brief_title>Study Determine Safety , Tolerability , Pharmacokinetic ( PK ) Profile EGT0001474 Healthy Volunteers</brief_title>
	<detailed_description>EGT0001474 inhibitor human sodium dependent glucose co-transporter II develop treatment Type II Diabetes mellitus . This singe center , Phase-1 , double blind , placebo control , dose escalation study single multiple ascend dos EGT0001474 healthy male female subject . In part-1 , subject randomize receive single dos EGT0001474 2.5-150 mg placebo ratio 3:1 . In part-2 , subject randomize receive 14 daily dos EGT0001474 10 , 50 150 mg placebo ratio 4:1 . When various dos analyse , maximum dose 150 mg find tolerable . Although serious adverse event , mild adverse event observe . This study provide information human safety , tolerability , PK pharmacodynamic effect EGT0001474 .</detailed_description>
	<criteria>Male female volunteer age 18 55 year inclusive . In good health . Female subject must surgically sterilize postmenopausal . Body mass index ( BMI ) 18 kg/m2 30 kg/m2 inclusive . Nonsmoker . Negative drug alcohol screen . Abnormal ECG Sitting blood pressure 140/90 mmHg 2 evaluation least 10 minute apart screen Treatment investigational drug within 30 day 7 halflives , whichever longer . Previous treatment EGT0001474 . History drug abuse . Febrile illness within 5 day prior first dose study medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Diabetes Mellitus Type 2</keyword>
</DOC>